Remepy, the pioneer of Hybrid Drugs, announced the closing of a $36 million Series A financing round led by O.G. Venture Partners and M Ventures, the corporate strategic venture arm of Merck KGaA, Darmstadt, Germany, with participation of existing and new investors including NFX, Vine Ventures, Qumra Capital, TechAviv, 97212 Ventures, Fresh Fund, PsyMed Ventures, Tadmor Group, Key1 Capital, and IT-Farm Corp.

The proceeds will accelerate the Company's pharmaceutical co-development partnerships and the expansion of its Hybrid Drug pipeline and platform, as well as fund the global Phase III clinical development of Hybridopa, Remepy's lead program for Parkinson's disease that will commence in Q4 2026. This funding brings the total capital raised by the Company to $62 million.